TARS
Tarsus Pharmaceuticals, Inc. NASDAQ Listed Oct 16, 2020$63.16
+0.98%
vs $62.55
Mkt Cap $2.6B
52w Low $38.82
55.7% of range
52w High $82.51
50d MA $63.23
200d MA $68.26
P/E (TTM)
—
EV/EBITDA
—
P/B
7.7x
Debt/Equity
0.3x
ROE
-19.3%
P/FCF
-118.3x
RSI (14)
63.40
ATR (14)
$2.68
Beta
0.63
50d MA
$63.23
200d MA
$68.26
Avg Volume
706.1K
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.
15440 Laguna Canyon Road · Irvine, CA 92618 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 6, 2026 | AMC | -0.40 | -0.16 | +60.0% | 64.76 | -3.2% | -1.2% | -4.3% | -2.5% | +0.3% | +8.1% | — |
| Feb 23, 2026 | AMC | -0.10 | -0.20 | -94.2% | 69.59 | +7.1% | +7.8% | -3.1% | +4.4% | -0.5% | +2.5% | — |
| Nov 4, 2025 | AMC | -0.35 | -0.30 | +14.3% | 71.50 | -4.2% | -4.6% | -0.2% | +0.2% | +6.7% | +3.9% | — |
| Aug 6, 2025 | AMC | -0.33 | -0.48 | -45.5% | 41.64 | +8.0% | +15.2% | -0.2% | +4.6% | +2.6% | +2.6% | — |
| May 1, 2025 | AMC | -0.69 | -0.64 | +7.2% | 50.30 | -2.8% | -5.8% | +1.4% | -3.2% | +1.9% | -0.4% | — |
| Feb 25, 2025 | AMC | -0.68 | -0.60 | +11.8% | 41.29 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% | — |
| Nov 13, 2024 | AMC | -0.94 | -0.61 | +35.1% | 46.51 | +9.7% | +0.3% | -3.9% | -0.4% | +5.1% | -0.7% | — |
| Aug 8, 2024 | AMC | -0.98 | -0.88 | +10.2% | 23.61 | +14.4% | +13.7% | -2.4% | +0.9% | +0.8% | +1.1% | — |
| May 8, 2024 | AMC | -1.15 | -1.01 | +12.2% | 37.35 | +13.8% | -8.9% | +8.7% | +3.7% | -1.0% | +1.3% | — |
| Feb 27, 2024 | AMC | -1.37 | -1.31 | +4.4% | 39.22 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% | — |
| Nov 9, 2023 | AMC | -1.40 | -1.28 | +8.6% | 15.57 | +9.6% | +12.2% | -1.7% | +4.4% | +0.1% | -1.1% | — |
| Aug 10, 2023 | AMC | -1.08 | -1.17 | -8.3% | 17.01 | -1.7% | -1.1% | +0.1% | +1.0% | -1.4% | -1.7% | — |
| May 9, 2023 | AMC | -0.95 | -0.88 | +7.4% | 16.09 | +2.5% | +3.8% | +2.2% | -3.3% | +0.4% | -1.9% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 24 | Oppenheimer | Reiterates | Outperform | $98 | $60.97 | $61.07 | +0.2% | +0.8% | -0.8% | +1.9% | -2.3% | +4.8% |
| Feb 25 | Guggenheim | Maintains | Buy → Buy | — | $75.01 | $74.97 | -0.1% | -3.1% | +4.4% | -0.5% | +2.5% | -1.1% |
| Feb 25 | Oppenheimer | Maintains | Outperform → Outperform | — | $75.01 | $74.97 | -0.1% | -3.1% | +4.4% | -0.5% | +2.5% | -1.1% |
| Nov 5 | Guggenheim | Maintains | Buy → Buy | — | $71.50 | $68.50 | -4.2% | -4.6% | -0.2% | +0.2% | +6.7% | +3.9% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $72.93 | $73.99 | +1.5% | -2.4% | -0.5% | -3.0% | -0.6% | -3.3% |
| May 5 | Goldman Sachs | Maintains | Neutral → Neutral | — | $47.36 | $46.95 | -0.9% | +1.4% | -3.2% | +1.9% | -0.4% | -5.0% |
| May 2 | Guggenheim | Maintains | Buy → Buy | — | $50.30 | $48.89 | -2.8% | -5.8% | +1.4% | -3.2% | +1.9% | -0.4% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $44.54 | $43.80 | -1.7% | -2.2% | +6.7% | -4.0% | +5.7% | -0.1% |
| Feb 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $41.29 | $42.35 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% |
| Feb 26 | Guggenheim | Maintains | Buy → Buy | — | $41.29 | $42.35 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% |
| Feb 26 | Barclays | Maintains | Overweight → Overweight | — | $41.29 | $42.35 | +2.6% | +3.1% | +2.3% | +2.1% | -4.0% | +4.2% |
| Feb 24 | Guggenheim | Maintains | Buy → Buy | — | $47.84 | $48.20 | +0.8% | -4.8% | -9.3% | +3.1% | +2.3% | +2.1% |
| Feb 10 | Guggenheim | Maintains | Buy → Buy | — | $52.95 | $53.33 | +0.7% | -2.2% | -1.0% | +2.2% | -0.2% | -3.8% |
| Jan 27 | Barclays | Maintains | Overweight → Overweight | — | $48.78 | $48.69 | -0.2% | +5.5% | -0.8% | +3.9% | -2.5% | +3.9% |
| Jan 22 | Oppenheimer | Maintains | Outperform → Outperform | — | $46.74 | $46.73 | -0.0% | +2.9% | +2.1% | -0.7% | +5.5% | -0.8% |
| Nov 15 | Goldman Sachs | Maintains | Neutral → Neutral | — | $46.65 | $46.50 | -0.3% | -3.9% | -0.4% | +5.1% | -0.7% | -0.4% |
| Nov 14 | Oppenheimer | Maintains | Outperform → Outperform | — | $46.51 | $51.00 | +9.7% | +0.3% | -3.9% | -0.4% | +5.1% | -0.7% |
| Aug 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $23.61 | $27.00 | +14.4% | +13.7% | -2.4% | +0.9% | +0.8% | +1.1% |
| May 13 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $37.00 | $37.00 | +0.0% | +3.7% | -1.0% | +1.3% | +0.2% | -0.9% |
| May 10 | Barclays | Maintains | Overweight → Overweight | — | $34.04 | $34.36 | +0.9% | +8.7% | +3.7% | -1.0% | +1.3% | +0.2% |
| May 9 | Oppenheimer | Maintains | Outperform → Outperform | — | $37.35 | $42.50 | +13.8% | -8.9% | +8.7% | +3.7% | -1.0% | +1.3% |
| Mar 6 | Jefferies | Maintains | Buy → Buy | — | $35.77 | $36.38 | +1.7% | +1.9% | -2.6% | -6.1% | -8.5% | +0.4% |
| Feb 29 | Goldman Sachs | Maintains | Neutral → Neutral | — | $37.87 | $38.89 | +2.7% | +0.9% | -3.3% | -0.2% | -3.0% | +1.9% |
| Feb 28 | Oppenheimer | Maintains | Outperform → Outperform | — | $39.22 | $40.40 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% |
| Feb 28 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $39.22 | $40.40 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% |
| Feb 28 | Barclays | Maintains | Overweight → Overweight | — | $39.22 | $40.40 | +3.0% | -3.4% | +0.9% | -3.3% | -0.2% | -3.0% |
| Nov 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $15.57 | $17.07 | +9.6% | +12.2% | -1.7% | +4.4% | +0.1% | -1.1% |
| Sep 11 | Guggenheim | Maintains | Buy → Buy | — | $16.05 | $16.47 | +2.6% | +5.8% | -3.2% | -8.8% | -1.6% | +9.4% |
| Aug 14 | Guggenheim | Maintains | Buy → Buy | — | $16.82 | $16.73 | -0.5% | +0.1% | +1.0% | -1.4% | -1.7% | +3.9% |
| Aug 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $17.01 | $16.72 | -1.7% | -1.1% | +0.1% | +1.0% | -1.4% | -1.7% |
| Jul 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.04 | $18.83 | +4.4% | +10.2% | +15.7% | -0.3% | -3.9% | -17.0% |
| Jun 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $18.25 | $18.45 | +1.1% | -6.0% | -0.8% | +5.1% | -0.5% | +1.6% |
| Jun 16 | Guggenheim | Maintains | Buy → Buy | — | $18.62 | $18.86 | +1.3% | -0.6% | +3.0% | -3.7% | -2.0% | +1.4% |
| May 18 | Guggenheim | Maintains | Buy → Buy | — | $15.93 | $16.31 | +2.4% | +1.3% | +0.2% | +0.5% | +1.6% | -2.4% |
| May 8 | Oppenheimer | Maintains | Outperform → Outperform | — | $15.35 | $15.35 | +0.0% | +1.6% | +3.2% | +3.8% | +2.2% | -3.3% |
| Mar 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $14.31 | $14.06 | -1.7% | -4.0% | -2.3% | -5.0% | +2.4% | -1.1% |
| Aug 1 | Barclays | Maintains | Overweight → Overweight | — | $15.02 | $15.95 | +6.2% | +1.9% | +8.8% | +3.2% | -0.2% | -0.3% |
| Dec 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $24.13 | $24.87 | +3.1% | +11.4% | -4.2% | +0.7% | -1.6% | -3.6% |
| Nov 23 | Oppenheimer | Maintains | Outperform → Outperform | — | $25.25 | $26.42 | +4.6% | +7.7% | +1.8% | -9.7% | +10.3% | -3.6% |
| Oct 8 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $22.12 | $23.59 | +6.6% | +11.1% | -1.5% | +10.8% | +10.7% | -5.3% |
| Jun 29 | Raymond James | Maintains | Strong Buy → Strong Buy | — | $28.49 | $29.53 | +3.7% | +5.4% | -3.5% | +0.1% | -1.2% | +0.4% |
| Nov 10 | Jefferies | Maintains | Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
| Nov 10 | Ladenburg Thalmann | Maintains | Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
| Nov 10 | BofA Securities | Maintains | Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
| Nov 10 | Raymond James | Downgrade | Strong Buy → Buy | — | $23.19 | $23.90 | +3.1% | -8.6% | +1.0% | +3.9% | +10.2% | +2.0% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| Jun 16, 2026 | Farrow Jeffrey SOff | See Remarks | Sell | 14,396 | $60.95 | $877K | 56,801 | +0.98% | — |
| Jun 15, 2026 | Goodrich KatherineDir | — | Sell | 2,954 | $62.08 | $183K | 2,233 | +0.98% | — |
| Jun 15, 2026 | LINK WILLIAM J PHDDir | — | Sell | 1,928 | $62.94 | $121K | 106,786 | +0.98% | — |
| Jun 15, 2026 | LINK WILLIAM J PHDDir | — | Sell | 10,572 | $61.97 | $655K | 108,714 | +0.98% | — |
8-K
Tarsus Pharmaceuticals, Inc. -- 8-K Filing
Tarsus Pharmaceuticals nearly tripled XDEMVY sales to $451.4 million in 2025, projects over $2 billion peak sales potential, and advances pipeline candidates TP-04 and TP-05 into Phase 2 trials.
Feb 23
8-K · 5.02
!!! Very High
Tarsus Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Tarsus Pharmaceuticals appointed David E.I. Pyott as a Class III director, adding experienced leadership to its board governance.
Feb 18
Institutional (13F) — Top 20
All ↗
| # | Manager | Shares | Value | Chg | Period |
|---|---|---|---|---|---|
| 1 | Morgan Stanley | 4,081,484 | $334M | Added | Dec 2025 |
| 2 | Rtw Investments, Lp | 3,346,025 | $235M | — | Mar 2026 |
| 3 | Jennison Associates Llc | 2,230,069 | $183M | Reduced | Dec 2025 |
| 4 | Janus Henderson Group Plc | 2,240,963 | $157M | New | Mar 2026 |
| 5 | Vanguard Capital Management Llc | 1,760,541 | $124M | New | Mar 2026 |
| 6 | Tang Capital Management Llc | 1,188,624 | $97M | Reduced | Dec 2025 |
| 7 | Assenagon Asset Management S.a. | 1,280,194 | $90M | Added | Mar 2026 |
| 8 | Bank Of America Corp /de/ | 1,194,377 | $84M | Added | Mar 2026 |
| 9 | Lord, Abbett & Co. Llc | 842,313 | $59M | Reduced | Mar 2026 |
| 10 | D.e. Shaw & Co | 791,146 | $55M | Added | Mar 2026 |
| 11 | Invesco Ltd. | 742,497 | $52M | Reduced | Mar 2026 |
| 12 | Fmr Llc | 733,334 | $51M | Added | Mar 2026 |
| 13 | Toronto Dominion Bank | 510,253 | $42M | Reduced | Dec 2025 |
| 14 | Millennium Management | 564,579 | $40M | Added | Mar 2026 |
| 15 | Clearbridge Investments, Llc | 545,351 | $38M | Added | Mar 2026 |
| 16 | Northern Trust Corp | 352,957 | $25M | Added | Mar 2026 |
| 17 | Vanguard Portfolio Management Llc | 335,889 | $24M | New | Mar 2026 |
| 18 | Franklin Resources Inc | 333,676 | $23M | Reduced | Mar 2026 |
| 19 | Ensign Peak Advisors, Inc | 332,982 | $23M | Reduced | Mar 2026 |
| 20 | Mpm Bioimpact Llc | 329,750 | $23M | — | Mar 2026 |
Mutual Funds / ETFs (N-PORT) — Top 20
All ↗
Valuation
Market Cap
$2.64B
Enterprise Value
$2.30B
P/E (TTM)
—
Forward P/E
—
PEG Ratio
1.07x
P/B
7.68x
P/S
4.93x
P/FCF
-118.29x
EV/EBITDA
—
Shares Out
41.8M
Financials (TTM)
Revenue
$535.1M
Net Income
-$48.3M
EBITDA
-$40.2M
Free Cash Flow
-$22.3M
Op Cash Flow
-$12.5M
EPS Basic
$-1.59
EPS Diluted
$-1.14
EPS Forward
$-0.72
Gross Margin
90.4%
Op Margin
-9.5%
Net Margin
-9.0%
Balance Sheet
Total Assets
$562.2M
Total Liab.
$218.7M
Total Equity
$343.4M
Cash
$417.3M
LT Debt
$83.0M
Book Value/Sh
$8.22
Debt/Equity
0.27x
Current Ratio
3.85
Quick Ratio
3.82
Returns & Growth
ROE
-19.3%
ROA
-11.8%
ROIC
-16.6%
Rev Growth YoY
+146.7%
EPS Growth YoY
+48.2%
Price Returns
2W
-8.9%
1M
-6.6%
3M
-21.3%
6M
-25.7%
12M
+38.3%
Technicals
52W High
$82.51
52W Low
$38.82
50d MA
$63.23
200d MA
$68.26
RSI (14)
63.40
ATR (14)
$2.68
Beta
0.63
Avg Volume
706K
Dividends
Div Rate
$0.00
Div Yield
—
Frequency
—
Ex-Div Date
—
Analyst Price Targets
Consensus
$89.33
High
$100.00
Low
$68.00
Median
$100.00
Data updated apr 27, 2026 3:59am
· Source: financialmodelingprep.com